Related Experiment Videos

[Effect of carvedilol on lipid peroxidation in patients with stable angina]

Jan Kowalski1, Jan Błaszczyk, Marcin Kowalski

  • 1Katedra Rehabilitacji z Klinika Chorób Wewnetrznych i Rehabilitacji Kardiologicznej UM w Łodzi.

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|September 20, 2007
PubMed

Insights

Carvedilol effectively reduces lipid peroxidation in patients with stable angina. This study shows that carvedilol treatment lowers malondialdehyde (MDA) levels, a marker of oxidative stress, in patients with this cardiovascular condition.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Stable angina is associated with increased oxidative stress and lipid peroxidation.
  • Malondialdehyde (MDA) is a key biomarker for assessing lipid peroxidation and tissue injury.

Purpose of the Study:

  • To investigate the effect of carvedilol on lipid peroxidation in patients with stable angina.
  • To evaluate changes in MDA concentration following carvedilol administration.

Main Methods:

  • A study involving 30 patients with stable angina treated with escalating doses of carvedilol (12.5-50 mg/day).
  • A control group of 12 healthy subjects was included for comparison.
  • Plasma and erythrocyte MDA levels were measured before and at 4, 8, and 12 weeks after therapy initiation.

Main Results:

  • Patients with stable angina exhibited significantly higher MDA concentrations compared to healthy controls.
  • Carvedilol therapy led to a significant decrease in MDA levels at 4, 8, and 12 weeks.
  • MDA levels in patients approached those of healthy subjects after 8 and 12 weeks of treatment.

Conclusions:

  • Carvedilol demonstrates a significant inhibitory effect on lipid peroxidation in patients with stable angina.
  • The findings suggest carvedilol may offer cardioprotective benefits by mitigating oxidative stress.

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...